A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of YZJ-5053 Tablets in Participants With Advanced Solid Tumors
Latest Information Update: 25 Jan 2024
At a glance
- Drugs YZJ 5053 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Haiyan Pharmaceutical Technology
Most Recent Events
- 25 Jan 2024 New trial record